Profile data is unavailable for this security.
About the company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
- Revenue in USD (TTM)3.18bn
- Net income in USD-888.18m
- Incorporated2019
- Employees6.77k
- LocationBiontech SEAn der Goldgrube 12MAINZ 55131GermanyDEU
- Phone+49 49 613190840
- Fax+49 61 319084390
- Websitehttps://www.biontech.com/
Mergers & acquisitions
| Acquired company | 22UA:GER since announced | Transaction value |
|---|---|---|
| Curevac NV | 1.23% | 1.55bn |
| Biotheus Inc | -7.09% | 800.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insmed Inc | 381.03m | -1.01bn | 19.76bn | 1.27k | -- | 191.09 | -- | 51.87 | -5.95 | -5.95 | 2.21 | 0.5451 | 0.2573 | 0.9753 | 8.98 | 299,787.60 | -68.42 | -44.83 | -88.04 | -51.79 | 76.49 | 77.08 | -265.93 | -226.78 | 5.44 | -31.80 | 0.9194 | -- | 19.17 | 21.66 | -21.91 | -- | -12.30 | -- |
| Summit Therapeutics Inc | 0.00 | -240.76m | 20.52bn | 159.00 | -- | 59.51 | -- | -- | -0.3309 | -0.3309 | 0.00 | 0.4643 | 0.00 | -- | -- | 0.00 | -85.89 | -78.31 | -95.86 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| BioNTech SE - ADR | 3.18bn | -888.18m | 26.69bn | 6.77k | -- | 1.22 | -- | 8.38 | -3.69 | -3.69 | 13.23 | 91.29 | 0.1264 | 1.46 | 2.10 | 470,221.10 | -3.53 | 26.29 | -3.80 | 30.47 | 84.03 | 83.89 | -27.89 | 46.16 | 10.02 | -- | 0.0152 | 4.85 | -27.96 | 90.87 | -171.51 | -- | 44.79 | -- |
| Iqvia Holdings Inc | 15.50bn | 1.33bn | 28.24bn | 89.00k | 22.24 | 4.76 | 11.51 | 1.82 | 7.34 | 7.34 | 85.31 | 34.33 | 0.5751 | -- | 4.63 | 176,102.30 | 4.97 | 4.03 | 6.65 | 5.17 | 34.72 | 34.47 | 8.64 | 7.28 | -- | 3.65 | 0.7054 | 0.00 | 2.81 | 6.80 | 1.10 | 48.36 | 0.678 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 31 Mar 2025 | 8.16m | 3.39% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2025 | 4.90m | 2.04% |
| Flossbach von Storch SEas of 31 Mar 2025 | 4.26m | 1.77% |
| PRIMECAP Management Co.as of 31 Mar 2025 | 4.05m | 1.68% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 31 Mar 2025 | 1.81m | 0.75% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2025 | 1.43m | 0.59% |
| FIAM LLCas of 31 Mar 2025 | 1.33m | 0.55% |
| BNP Paribas Financial Marketsas of 31 Mar 2025 | 1.20m | 0.50% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 1.09m | 0.45% |
| Strategic Advisers LLCas of 31 Mar 2025 | 1.05m | 0.44% |
